
Peripal AG signs agreement with Mologic Ltd. to distribute PERiPLEX POC Diagnostic for Peritoneal Dialysis in key European countries

Peripal AG is developing support devices, that enable more patients worldwide to stay home and ensure a safe therapy. Together with Mologic Ltd, a developer of powerful, personalised diagnostics we have signed an agreement to distribute PERiPLEX®, a rapid point-of-care (POC) test for the detection of infection in patients on peritoneal dialysis (PD). Peripal will supply PERiPLEX as part of a highly complementary product portfolio in the key European markets Germany, Italy, The Netherlands, Austria and Switzerland.

PERiPLEX detects two critical biomarkers of infection in PD waste fluid using a lateral flow immunoassay system and provides a visual result within 5 minutes. PERiPLEX is giving patients the confidence to monitor their dialysis at home. Peripal has developed a novel patient assist device for peritoneal dialysis and will enable the patients to connect the transfer set in a safe and easy way at home. PERiPLEX is complementing the existing portfolio of Peripal and will help us to bring enhanced safety standards to the patients at home and improve their quality of life.

The PERiPLEX technology was developed following a collaborative project with Cardiff University Medical School, funded by the National Institute of Health Research (NIHR).

To find out more about PERiPLEX visit www.peripal.com or give us a call on +41 44 221 95 40.